Dry Powder Inhaler Manufacturing: Best Practices For Next-Generation Therapies

Dry powder inhaler (DPI) manufacturing is evolving quickly as next‑generation therapies demand greater precision, tighter quality control, and more flexible production strategies. Achieving consistent performance requires a disciplined approach to particle engineering, blend uniformity, environmental control, and device compatibility — each of which directly influences aerodynamic behavior and patient usability.

As formulations become more complex and regulatory expectations intensify, teams must integrate robust analytical methods, repeatable processes, and proactive risk management to ensure reliable scale‑up from early development through commercial readiness. Success also depends on strong coordination across formulation scientists, process engineers, and device specialists to maintain alignment throughout each manufacturing stage.

Exploring these best practices provides a practical understanding of how to mitigate variability, protect product integrity, and support the efficient progression of inhaled therapies. Access the full article for deeper insight into the technical considerations shaping the future of DPI manufacturing.